Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and OPC in Prostate Cancer
NCT03465345Phase 1Withdrawn
- Sponsor
- Medical University of South Carolina
- Start
- Jul 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of metformin in prostate cancer (PCa), sponsored by Medical University of South Carolina. Primary endpoint: Maximum tolerated dose at 112 days. Planned start Jul 2018; status: withdrawn.
02
Drugs
metformin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03465345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465345.